Scholarlink

<p>Warts are a common skin disease caused by the human papillomavirus. While many treatments exist, none are entirely effective. Our objective is to study the efficacy and safety of a 577 nm diode laser in the treatment of cutaneous warts due to its strong oxyhemoglobin absorption for targeting wart vasculature. Patients with common warts (n = 31) were enrolled in this prospective study. Patients with history of poor wound healing (immunosuppressed or uncontrolled diabetics) and those with a scar and keloid formation, Koebner phenomenon, or active infection at the local site are excluded from the study. Patients received sessions every two weeks of 577 nm diode laser treatment, continuous mode, 1 mm spot and 3–5 W power according to wart size; sessions were repeated every 2 weeks until full clearance was achieved. Patients were followed up clinically and by photography every 2 weeks and 3 months after the final session. This prospective study included 31 patients clinically diagnosed with common warts; their mean age was 22.77 ± 4.74 years, 16 (51.6%) patients were males and 15 (48.4%) were females, 18 (58.06%) patients were skin type IV and 13 (41.94%) cases were skin type V and the mean duration of warts was 6.7 ± 4.24 months. Lesions were present in the hands in 14 patients (45.2%), the feet in 8 patients (25.8%), upper extremities (3 patients, 9.7%), lips (3 patients, 9.7%), and scalp (3 patients, 9.7%). All patients were treated with a 577 nm diode laser session every 2 weeks until complete improvement to maximum 3 sessions. Complete improvement was achieved in 71% of patients (22/31) after one session and in all patients after three sessions. The mean healing time was 1.34 ± 0.56 weeks. Wart improvement significantly correlated with the number of wart (P ≤ 0.05), but not with patient age, sex, skin types or wart duration (P &gt; 0.05). Most patients reported no side effects. However, post-inflammatory hyperpigmentation occurred in 1 case (3.2%), and recurrence in 3 cases (9.6%). The 577-diode laser is a safe and effective wart treatment modality, with efficacy correlated to the number of warts. Clinical trial number: Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The efficacy and safety of a 577 nm diode laser in the treatment of cutaneous warts: A prospective single-arm study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Essamelden Mohamed

摘要

Warts are a common skin disease caused by the human papillomavirus. While many treatments exist, none are entirely effective. Our objective is to study the efficacy and safety of a 577 nm diode laser in the treatment of cutaneous warts due to its strong oxyhemoglobin absorption for targeting wart vasculature. Patients with common warts (n = 31) were enrolled in this prospective study. Patients with history of poor wound healing (immunosuppressed or uncontrolled diabetics) and those with a scar and keloid formation, Koebner phenomenon, or active infection at the local site are excluded from the study. Patients received sessions every two weeks of 577 nm diode laser treatment, continuous mode, 1 mm spot and 3–5 W power according to wart size; sessions were repeated every 2 weeks until full clearance was achieved. Patients were followed up clinically and by photography every 2 weeks and 3 months after the final session. This prospective study included 31 patients clinically diagnosed with common warts; their mean age was 22.77 ± 4.74 years, 16 (51.6%) patients were males and 15 (48.4%) were females, 18 (58.06%) patients were skin type IV and 13 (41.94%) cases were skin type V and the mean duration of warts was 6.7 ± 4.24 months. Lesions were present in the hands in 14 patients (45.2%), the feet in 8 patients (25.8%), upper extremities (3 patients, 9.7%), lips (3 patients, 9.7%), and scalp (3 patients, 9.7%). All patients were treated with a 577 nm diode laser session every 2 weeks until complete improvement to maximum 3 sessions. Complete improvement was achieved in 71% of patients (22/31) after one session and in all patients after three sessions. The mean healing time was 1.34 ± 0.56 weeks. Wart improvement significantly correlated with the number of wart (P ≤ 0.05), but not with patient age, sex, skin types or wart duration (P > 0.05). Most patients reported no side effects. However, post-inflammatory hyperpigmentation occurred in 1 case (3.2%), and recurrence in 3 cases (9.6%). The 577-diode laser is a safe and effective wart treatment modality, with efficacy correlated to the number of warts. Clinical trial number: Not applicable.